Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update

• Acurx is proud to sponsor this inaugural Scientific Symposium of the Peggy Lillis Foundation (PLF) for C. Diff Education & Advocacy
• An update of ibezapolstat Ph2b clinical and microbiome results was presented
• Preparation continues to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection (CDI)
• Acurx continues preparation to submit requests for regulatory guidance to initiate clinical trials in the European Union to be followed by Japan, Canada and the United Kingdom (TADAWUL:)
• Ibezapolstat has previously received FDA QIDP and Fast-Track Designation from FDA

STATEN ISLAND, N.Y., Nov. 18, 2024 /PRNewswire/ — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, with its lead antibiotic candidate, ibezapolstat, preparing to advance to international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI). The Company today announced its support and participation in the Inaugural Peggy Lillis Foundation (virtual) Scientific Symposium, held on Friday, November 15, 2024.

Acurx’s Executive Chairman, Bob DeLuccia, delivered opening remarks for the symposium  which assembled experts and thought leaders from around the world to present state-of-the art updates regarding C difficile Infection and therapeutic options. Topics covered included epidemiology, bacterial physiology, risk factors for infections, and new and emerging treatment modalities. The Symposium also included testimonials from patients who survived  CDI.

Kevin Garey, PharmD, MS, FIDSA, Professor and Chair, University of Houston College of Pharmacy, Principal Investigator for microbiology and microbiome aspects of the  ibezapolstat  clinical  trial  program, and  Acurx  Scientific  Advisory  Board  member, delivered a presentation entitled:  “Ibezapolstat Preserves Key Clostridium Leptum Species: Microbiome Results from the Phase 2, Randomized, Double-Blind Study.”

According to Dr. Garey: “In contrast to  patients dosed with vancomycin, ibezapolstat has consistently shown in the phase 1 and 2 studies that it promotes the growth of beneficial Actinobacteria important for short chain fatty acid production and Clostridiales important for bile acid homeostasis. At the same time, it does not promote the overgrowth of potentially harmful Proteobacteria.” He further added:…